Krystal Biotech
Highly Engaged Employees
Highly Engaged EmployeesManufacturing · Pennsylvania, United States · 201-500 Employees
View Company Info for Free
Overview
Headquarters
2100 Wharton St Ste 701, Pittsburgh, Pen...Phone Number
(412) 586-5830Website
www.krystalbio.comRevenue
$417.3 MillionStock Symbol
KRYSIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
4
4
1
1
1
1
About Krystal Biotech
Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). The company also develops KB105, which is in Phase 1/2 clinical trials for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for treating netherton syndrome; KB407 that is in Phase 1 clinical trials for treating cystic fibrosis; KB707 that is in Phase 1 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in PittsRead more
Krystal Biotech Org Chart
ZL
Global Senior Director, Pricing
MT
Senior Director, Revenue Accounting
AR
Associate Director, Pricing & Contracting
AS
Associate Director, Pricing & Contracting
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Krystal Biotech your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check if Krystal Biotech has recently received funding, and reach out quickly before it becomes old news!
Website visits: Recent activity has been detected on your website
Check out if Krystal Biotech is spiking on competitors!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Funding: Get notified immidiatlly once Krystal Biotech has new funding data
Click to see if Krystal Biotech had a recent Job posting/layoffs
Krystal Biotech, which may be a good buyer, showed buying intent in Masked Content Topic
Congratulate Masked Content for being promoted to Masked Content at Krystal Biotech
Product Launch: Get notified when Krystal Biotech launches new products
Earning: See what the market has to say on Krystal Biotech recently announced quarterly report
Recommended Actions
Find VP level buyers at Krystal Biotech
Find 2 more new buyers
Compare Similar Companies to Krystal Biotech
Compare insights from companies similar to Krystal Biotech, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
$15.5M
51-200
Private
$31M
2003
JH
James HavilandVice President, Quality Assurance, Regulatory Compliance & Regulatory Affairs
Company Profile Activity
Activity Insights
Krystal Biotech is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Krystal Biotech is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Krystal Biotech.
Krystal Biotech Tech Stack
A closer look at the technologies used by Krystal Biotech
Most Recent Scoops
Open Position
Open Position
Person-Based
Product Launch, Pharmaceuticals
Person-Based
Earnings, Pharmaceuticals, Finance
Person-Based
Earnings, Business Finance, Finance
Krystal Biotech News & Media
Krystal Biotech Announces United Kingdom MHRA Approval of VYJUVEK® for the Treatment of Dystrophic Epidermolysis Bullosa
VYJUVEK approved for the treatment of DEB from birth with flexible administration options similar to those already granted in the United States, European Union, and JapanKrystal Biotech to Present at BofA Securities 2026 Health Care Conference
PITTSBURGH, May 07, 2026 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS) today announced that the Company will participate in the BofA Securities 2026 Health Care Conference on May 13, 2026, in Las Vegas. Krish S. Krishnan, Chairman and Chief Executive Officer, will take part in a fireside chat scheduled at 11:20 am PT and host investor meetings throughout the day.Krystal Biotech Announces First Quarter 2026 Financial and Operating Results
$116.4 million in 1Q VYJUVEK global revenue and $846.7 million since launchKrystal Biotech to Present at Upcoming Scientific Conferences
PITTSBURGH, April 30, 2026 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS) announced today that the Company will be presenting on multiple programs at upcoming scientific conferences being held in May and June.
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Krystal Biotech
Sign Up For FreeTo access detailed company insights
Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). The company also develops KB105, which is in Ph... Read More
